Nektar Therapeutics (NKTR.OQ)
59.00USD
21 Sep 2018
$0.56 (+0.96%)
$58.44
$58.98
$59.66
$58.22
2,526,668
1,246,379
$111.36
$21.13
About
Overall
| Beta: | 1.38 |
| Market Cap(Mil.): | $3,878.49 |
| Shares Outstanding(Mil.): | 156.33 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| NKTR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 32.76 |
| EPS (TTM): | -1.40 | -- | -- |
| ROI: | -53.15 | 1.79 | 14.61 |
| ROE: | -- | 3.28 | 16.33 |
Bristol-Myers cancer ruling hits shares after strong earnings
NEW YORK Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.
UPDATE 2-Bristol-Myers cancer ruling hits shares after strong earnings
NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.
Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales
NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday posted better-than-expected second-quarter earnings and raised its full-year forecast on strong sales from its blockbuster cancer drug Opdivo and blood thinner Eliquis.
US STOCKS-Tech rally helps Wall St push higher, Nasdaq has record close
* Indexes gain: Dow 0.72 pct, S&P 0.45 pct, Nasdaq 0.69 pct (Updates to close, adds commentary)
US STOCKS-Technology rally helps Wall Street push higher
* Indexes gain: Dow 0.66 pct, S&P 0.41 pct, Nasdaq 0.57 pct (Updates to late afternoon, adds commentary, changes byline, adds New York dateline)
US STOCKS-Tech rally fuels Nasdaq to near record levels
* Indexes gain: Dow 0.76 pct, S&P 0.42 pct, Nasdaq 0.59 pct (Changes comment, adds details, updates prices)
US STOCKS-Wall Street higher as Apple leads tech rally
* Indexes gain: Dow 0.73 pct, S&P 0.27 pct, Nasdaq 0.28 pct (Changes comment, adds details, updates prices)
Mixed results for Bristol/Nektar combination in cancer trial
Chicago, June 3 Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations.
BRIEF-Nektar Therapeutics Says CEO Howard W. Robin's 2017 Total Compensation Was $18.1 Million
* NEKTAR THERAPEUTICS SAYS CEO HOWARD W. ROBIN'S 2017 TOTAL COMPENSATION WAS $18.1 MILLION – SEC FILING
BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors
* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS
Competitors
| Price | Chg | |
|---|---|---|
| Takeda Pharmaceutical Co Ltd (4502.T) | ¥4,713 | 0.00 |
| Eisai Co., Ltd (4523.T) | ¥10,270 | -330.00 |
| NOF CORPORATION (4403.T) | ¥3,645 | +20.00 |
| Dr.Reddy's Laboratories Ltd (REDY.NS) | Rs2,556.25 | -50.85 |
| Novo Nordisk A/S (NOVOb.CO) | kr.301.50 | +3.00 |
| Pfizer Inc. (PFE.N) | $44.06 | +0.31 |
| Novartis AG (NOVN.S) | CHF81.88 | -0.06 |
| Roche Holding Ltd. (ROG.S) | CHF235.15 | +0.10 |
| Roche Holding Ltd. (RO.S) | CHF235.40 | -1.20 |
| GlaxoSmithKline plc (GSK.L) | 1,531.40 | +45.60 |
Estimates